ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m…
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
Trogenix has raised £70m ($95m) in Series A financing to help bring its “Trojan horse” cancer treatment into clinical trials,…
Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an…
Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under management to…
The European Commission (EC) has sanctioned the use of Servier’s Voranigo (vorasidenib) to treat certain brain tumours, specifically non-enhancing grade…
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…